drugset / Trial / NCT02385318

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

NCT02385318

Phase 3 Completed 519 enrolled Padagis LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.

Timeline

Start
2015-02
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule

Indications